Trade-Ideas LLC identified

Intrexon

(

XON

) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Intrexon as such a stock due to the following factors:

  • XON has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $43.6 million.
  • XON has traded 221,566 shares today.
  • XON is down 3.3% today.
  • XON was up 7% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in XON with the Ticky from Trade-Ideas. See the FREE profile for XON NOW at Trade-Ideas

More details on XON:

Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. The stock currently has a dividend yield of 0.4%. Currently there are 4 analysts that rate Intrexon a buy, no analysts rate it a sell, and 3 rate it a hold.

The average volume for Intrexon has been 2.1 million shares per day over the past 30 days. Intrexon has a market cap of $3.7 billion and is part of the health care sector and drugs industry. Shares are up 12% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Intrexon as a

sell

. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself.

Highlights from the ratings report include:

  • XON has underperformed the S&P 500 Index, declining 22.35% from its price level of one year ago. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, INTREXON CORP's return on equity significantly trails that of both the industry average and the S&P 500.
  • INTREXON CORP has improved earnings per share by 35.8% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, INTREXON CORP reported poor results of -$0.84 versus -$0.03 in the prior year. This year, the market expects an improvement in earnings (-$0.68 versus -$0.84).
  • The gross profit margin for INTREXON CORP is currently very high, coming in at 77.85%. It has increased significantly from the same period last year. Regardless of the strong results of the gross profit margin, the net profit margin of -71.60% is in-line with the industry average.
  • Net operating cash flow has significantly increased by 896.97% to $52.90 million when compared to the same quarter last year. In addition, INTREXON CORP has also vastly surpassed the industry average cash flow growth rate of -27.19%.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.